Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.
The 2026 meeting in Denver features more than 265 hours of programming, real-world MASH treatment data, and late-breaking results in rare liver diseases.